Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 0.40 |
| ▸ | MMP3 | P08254 | 11/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462863 | 0.93 | DUT (0.38) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL4093293 | 0.88 | F2 (0.51) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL4093297 | 0.88 | F2 (0.51) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL2458573 | 0.84 | F2 (0.48) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL2458572 | 0.84 | F2 (0.48) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL318215 | 0.81 | MMP1 (0.53) | MMP1MMP3SRCACEMME | |
| SCHEMBL4089318 | 0.81 | F2 (0.43) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL4089316 | 0.81 | F2 (0.43) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL2463051 | 0.81 | F2 (0.43) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL318740 | 0.74 | INMT (0.42) | MMP1MMP3F10SRCACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026233-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090149443-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-2029581-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007126871-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149443-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPK1, MAPK4, BRIX1 | MMP1 2463/4885MMP3 3813/4885F2 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.